Streptomycin

As a classic aminoglycoside antibiotic, streptomycin blocks protein synthesis by irreversibly binding to the 30S subunit of bacterial ribosomes. It is the world's first antibiotic used for the clinical treatment of tuberculosis, and is still a core second-line drug for anti-tuberculosis combination therapy to date. Meanwhile, it has definite therapeutic effects on infections caused by sensitive bacteria such as brucellosis, plague and granuloma inguinale. It is mainly indicated for patients with Mycobacterium tuberculosis infections and people with moderate to severe infections caused by other sensitive Gram-negative bacilli. With a clinical application history of more than 70 years, it is an indispensable anti-infective drug in the public health prevention and control system.

The global streptomycin market size has stabilized in the range of 1.2 to 1.5 billion yuan in recent years, and the growth mainly comes from the demand for tuberculosis prevention and control in emerging markets and the expansion of the veterinary field. Affected by the centralized procurement policy in the domestic market, the price of preparations tends to be rational, and the concentration of API supply is relatively high. The production capacity of domestic enterprises accounts for more than 65% of the global total production capacity, making China the core supplier of streptomycin API in the world. There is no publicly verifiable segmented market growth rate data available at present.

The original research enterprise of streptomycin is Merck Group, and the original research brand name is Streptomycin. The compound patent of this variety has expired. The commonly used clinical dosage forms currently include streptomycin sulfate for injection, with mainstream specifications of 0.75g (750,000 units) and 1g (1,000,000 units). The original research streptomycin sulfate for injection has been included in the FDA Reference Listed Drug Catalog. The original research product has not been filed for reference in China, and the existing domestic reference preparations have been included in the *Collection of Listed Drugs in China*. According to the domestic API registration platform, there are currently 12 valid registration numbers for streptomycin sulfate API, among which 9 are in A status and can be supplied for domestic preparation production; more than 200 approvals have been granted for domestic streptomycin sulfate for injection to be marketed. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of streptomycin impurity reference standards, which can cover the qualitative and quantitative impurity requirements in the whole process from API production to preparation quality research. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. Meanwhile, the products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, helping pharmaceutical enterprises efficiently complete quality research and registration and declaration work.